All Companies

Abide Tx
Serine hy­dro­lase-tar­get­ed ther­a­peu­tics har­ness­ing the en­do­cann­abi­noid sys­tem to ad­dress neu­ro­log­i­cal and pain di­s­or­ders w. limit­ed or no treat­ment op­tions. Ph 2: Tourette Syn­drome on­go­ing with da­ta ex­pect­ed in 1Q20; Ph 1b: neu­ro­path­ic pain com­plete, with plans to ini­ti­ate Ph 2 in 1H19. [more in­for­ma­tion]
AcelRx Pharmaceuticals, Inc. [ACRX] US$229 MM MCap
Re­cent­ly launched DSU­VIA; rev-gen­er­at­ing in Q1. Plans to re­sub­mit Za­lvi­so NDA in US by YE [more in­for­ma­tion]
Pro­pri­e­tary Af­fi­body® molecules and Al­bu­mod plat­forms. 4 clin­i­cal / late-stage, pro­pri­e­tary pro­grams in­clud­ing pso­ri­a­sis, B-cell au­toim­mune dis­eas­es, & liv­er dis­eas­es. Pipe­line al­so in­cludes Dx imag­ing pro­gram tar­get­ing me­tastat­ic breast can­cer. [more in­for­ma­tion]
Affimed N.V. [AFMD] US$187 MM MCap
Mo­d­u­lar ROCK™plat­form en­abling mul­ti-spe­cif­ic NK / T-cell bi-and tri-spe­cif­ic Abs. Aug 2018 deal w Ge­nen­tech ($96M up­front / $5B po­ten­tial). – AFM13 in P1b (com­bo) in HL and P2a(mono) in CD30+lym­pho­ma [more in­for­ma­tion]
Amarin Corporation [AMRN] US$5,713 MM MCap
Vas­ce­pa: 1st and on­ly pure EPA ome­ga-3 fat­ty acid ap­proved to low­er trig­lyc­eride lev­els in adults. Pre­sent­ed (+) da­ta from RE­DUCE-IT CV Out­comes trial at AHA [more in­for­ma­tion]
Anterra Capital
An­ter­ra is the lead­ing biotech in­ves­tor in the plant and an­i­mal sci­ence in­dus­tries. An­ter­ra part­n­ers close­ly with biotech com­pa­nies to speed the ap­pli­ca­tion of emerg­ing tech­nolo­gies across life sci­ence sec­tors. Backed fi­nan­cial­ly and strate­g­i­cal­ly by Fi­del­i­ty and Rabobank, An­ter­ra is the pre­mi­er fund for plant and an­i­mal biotech in­vest­ing. [more in­for­ma­tion]
Ph3 ready hor­mone ther­a­py com­pany with an in­jectable, long-act­ing GnRH an­ta­g­on­ist for pros­tate can­cer and be­nign pro­stat­ic hy­per­pla­sia. An in­jectable en­ables ex­tend­ed drug ac­tiv­i­ty, which is im­por­tant for in­di­ca­tions with ac­tive oral an­ta­g­on­ists in late-stage de­vel­op­ment and al­so ap­proved agent(s). The safe­ty pro­file looks good with over 415 sub­jects dosed over 805 times. [more in­for­ma­tion]
CD40 ag­on­ist mAb; 170+ pts dosed (mono & com­bi sett­ings). 7 on­go­ing Ph 2s, undis­closed oc­u­lar dis­ease pro­gram in Ph 3. AACR: Ph 1b da­ta (w/Park­er Inst); col­labs w/BMY, MDACC, Yale, et al [more in­for­ma­tion]
Aptorum Group [APM] US$161 MM MCap
Ap­to­rum is a phar­ma­ceu­ti­cal com­pany ded­i­cat­ed to de­vel­op­ing and com­mer­cial­iz­ing a broad range of ther­a­peu­tic and di­ag­nos­tic tech­nolo­gies to tack­le un­met med­i­cal needs. Ap­to­rum is pur­su­ing ther­a­peu­tic and di­ag­nos­tic pro­jects in neu­rol­o­gy, in­fec­tious dis­eas­es, gas­troen­terol­o­gy, on­col­o­gy and other dis­ease ar­eas; [more in­for­ma­tion]
Asklepion Pharmaceuticals
Pri­vate, fo­cused on the de­vel­op­ment of IV Cit­rul­line for rare pe­di­a­tric dis­eas­es. First in­di­ca­tion, the pre­ven­tion of sig­ni­f­i­cant se­que­lae of pe­di­a­tric acute car­diopul­mo­nary by­pass-in­duced lung in­jury, Ph 3 trial is on­go­ing. [more in­for­ma­tion]
Assembly Biosciences, Inc. [ASMB] US$396 MM MCap
Nov­el, oral, live bio­ther­a­peu­tics ad­dress­ing dis­eas­es as­soc w mi­cro­biome. HBV pro­gram ad­vanc­ing mul­ti­ple drug can­di­dates; ful­ly in­te­grat­ed mi­cro­biome plat­form in­cludes ro­bust strain ID and se­lec­tion pro­cess (for strain iso­la­tion & growth). [more in­for­ma­tion]
Avacta [AVCT:LN] £32 MM MCap
It is based on a na­t­u­ral­ly oc­cur­ring hu­man pro­tein, en­gi­neered to be­have like an anti­body, but small­er, sim­pler, more ro­bust, easy to for­mat, cheap­er and quick­er to pro­duce, high­ly spe­cif­ic to the tar­get and non-im­muno­genic. [more in­for­ma­tion]
AxoGen [AXGN] US$846 MM MCap
Da­m­age or tran­sec­tion to pe­ripher­al nerves. Q1 revs $23.3M, 35% growth YoY; exp 2019 rev bt $109-$114M [more in­for­ma­tion]
Bellus Health [BLU.CN]
Its pipe­line of pro­jects in­cludes the Com­pany’s lead drug can­di­date BLU-5937 for chron­ic cough and sev­er­al other part­nered clin­i­cal-stage drug de­vel­op­ment pro­grams. BLU-5937, a high­ly se­lec­tive P2X3 an­ta­g­on­ist, has the po­ten­tial to be a best-in-class ther­a­peu­tic for chron­ic cough pa­tients who do not re­spond to cur­rent ther­a­pies. [more in­for­ma­tion]
BerGenBio [BGBIO:OS] NKr1,242 MM MCap
De­vel­op­ing first-in-class se­lec­tive Axl ki­nase in­hibi­tors for liquid and solid can­cers, lead can­di­date is bem­cen­tinib (BG­B324) n four com­pany-spon­sored trials. Stage 2 of Ph 2 com­bi­na­tion trial with bem­cen­tinib/KEYTRU­DA in NS­CLC ex­pect­ed in 1H19. Bem­cen­tinib/TARCE­VA Ph 2 com­bi­na­tion trial in first line EGFRm pa­tients re­port­ed that me­dian PFS sur­passed TARCE­VA monother­a­py. [more in­for­ma­tion]
Biohaven Pharmaceuticals, Inc [BHVN] US$2,677 MM MCap
Lead de­vel­op­ment pro­grams in­clude mul­ti­ple com­pounds across its CGRP re­cep­tor an­ta­g­on­ist and glu­ta­mate mo­d­u­la­tion plat­forms. In­ter­nal de­vel­op­ment and re­search with in­tel­lec­tu­al prop­er­ty li­censed from com­pa­nies and in­sti­tu­tions in­clud­ing BMS, As­traZene­ca, Yale Uni­ver­si­ty, Ca­ta­l­ent, ALS Bio­phar­ma and Mas­sachusetts Gen­er­al Hos­pi­tal. [more in­for­ma­tion]
BioPharmX [BPMX] US$9 MM MCap
De­vel­op­ing BPX-04 for rosacea, us­ing pro­pri­e­ta­ty hy­drophil­ic top­i­cal for­mu­la­tion tech­nol­o­gy. En­rolling Ph2b w da­ta exp in 2019. Com­plet­ed Ph 2b with BPX-01 in acne. [more in­for­ma­tion]
BioTime, Inc [BTX] US$159 MM MCap
Lead (Ph 2) cell re­place­ment can­di­date: OpRe­gen®, reti­nal pig­ment epithe­li­um tran­s­plant ther­a­py: Dry AMD. Lead cell de­liv­ery clin­i­cal pro­gram: Rene­via®: med de­vice de­vel­oped as al­ter­na­tive to adi­pose tis­sue trans­fer pro­ce­dures. Equi­ty in As­te­rias Bio­ther­a­peu­tics (NYSE: AST), On­co­Cyte Cor­po­ra­tion (NYSE: OCX), and AgeX Ther­a­peu­tics (pri­vate) [more in­for­ma­tion]
BlinkBio, Inc.
They have in­no­vat­ed a plat­form based on Tun­able Drug Con­ju­gate (TDCs) ther­a­pies used to di­rect­ly tar­get the de­liv­ery of toxins to tu­mors. The lead ther­a­peu­tic pro­gram tar­gets Fo­late Re­cep­tor al­pha and has been vali­dat­ed in the clin­ic by ADCs, pro­vid­ing a de-risked bench­mark for plat­form vali­da­tion and can­di­date de­vel­op­ment. [more in­for­ma­tion]
BrainStorm Cell Therapeutics Inc. [BCLI] US$111 MM MCap
NurOwn® au­tol­o­gous cell ther­a­py plat­form for neu­rode­gen­er­a­tive dis­eas­es. Lead can­di­date for ALS, Ph2 eval­u­at­ed 60 ALS pts w fa­vor­able safe­ty/tol­er­a­bil­i­ty. Ph3 cur­rent­ly en­rolling 200 pts across 6 US cen­ters; top-line da­ta ex­pect­ed in mid-2020. Se­cond in­di­ca­tion is pro­gres­sive MS - IND ac­cept­ed Dec 2018. [more in­for­ma­tion]
Caris Life Sciences
Pre­ci­sion medicine com­pany uti­l­iz­ing pro­pri­e­tary plat­forms to pro­vide on­col­o­gists with ac­tion­able treat­ment da­ta for can­cer and other com­plex dis­eas­es. [more in­for­ma­tion]
CASI Pharmaceuticals Inc. [CASI] US$302 MM MCap
Re­ceived MN­PA (f.k.a. CF­DA) ap­pro­val for EVOMELA® (mel­pha­lan for in­jec­tion: mul­ti­ple myelo­ma) on Dec 3, 2018; CF­DA re­view in progress for ZE­VALIN® and MAR­QI­BO® (in-li­censed from Spec­trum Phar­ma). Ac­qd 25 US FDA-ap­proved AN­DAS from San­doz in Jan 2018. [more in­for­ma­tion]
Catalyst Pharmaceuticals, Inc. [CPRX] US$365 MM MCap
Fir­dapse ap­proved 11/18, Q1 sales of $12m: 380 ac­tive LEMS pa­tients on ther­a­py (a/o May 9) [more in­for­ma­tion]
Cellular Biomedicine Group, Inc. [CBMG] US$332 MM MCap
This vali­dates CB­MG's in-house cell man­u­fac­tur­ing ca­pa­bil­i­ties de­vel­oped in part­n­er­ship with Gen­er­al Elec­tric and Ther­mo Fish­er. CB­MG's pro­pri­e­tary im­muno-on­col­o­gy pipe­line in­cludes BC­MA, CD22, TCR-T for HCC and TIL for the treat­ment of NS­CLC and other solid tu­mors. [more in­for­ma­tion]
CTI BioPharma [CTIC] US$50 MM MCap
Lead can­di­date pa­cri­tinib, oral ki­nase in­hibi­tor w spe­ci­fic­i­ty for JAK2, FLT3, IRAK1, and CS­F1R in Ph 2 for treat­ment of myelo­fi­bro­sis. Up­com­ing ca­t­alysts: pa­cri­tinib PAC203 Ph 2 da­ta - mid'19, ini­ti­a­tion of ph3 - Q3. [more in­for­ma­tion]
CureVac AG
Found­ing Co of mR­NA space (last round $1bn+). In­tra­tu­mo­ral ther­a­py Ph1 (mul­ti­ple onc in­di­ca­tions) ini­ti­at­ed Q4 17, ear­ly da­ta rep at SITC. First pt en­rolled Ph 1 pro­phy­lac­tic mR­NA ra­bies vax Oct 2018. Pro­phy­lac­tic in­fluen­za vax ini­ti­a­tion Ph 1 2020, OTC de­fi­cien­cy Ph 1 ini­ti­a­tion H219. In­ter­im da­ta /all trials: 2019. [more in­for­ma­tion]
Enzo Biochem, Inc. [ENZ] US$155 MM MCap
$100m revs in F18. Pi­oneer in molec­u­lar di­ag­nos­tics (Dx), lead­ing con­ver­gence of clin­i­cal lab­o­ra­to­ries, life sci­ences and IP through de­vt of unique Dx plat­form tech­nolo­gies pro­vid­ing nu­mer­ous ad­van­tages over pre­vi­ous stan­dards. [more in­for­ma­tion]
ESSA Pharma Inc. [EPIX] US$12 MM MCap
Sm molecule drugs: cas­tra­tion-re­sis­tant pros­tate can­cer. EPI-506, exp to en­ter clin­ic YE19 (se­cond-gen com­pound). De­vel­op­ing com­pounds bind­ing to N-ter­mi­nus of AR and block sig­nal­ing. MOA po­ten­tial­ly over­comes re­sis­tance mech­anisms cur­rent­ly seen in me­tastat­ic pros­tate can­cer. [more in­for­ma­tion]
Se­lec­tive in­hibi­tors of TGF Be­ta & EGFR path­ways. AACR: (+) Ph 1 da­ta. 3 on­go­ing Ph 2 trials (SCCHN, NS­CLC, TN­BC); ad­dl Ph 1 trials in IO, Sys­temic Scle­ro­sis & Myelo­fi­bro­sis [more in­for­ma­tion]
Genfit SA [GNFTF] US$875 MM MCap
$155m Mar 2019 US IPO; FDA BTD for Ela­fi­branor (4/19); (+) 36-mo DSMB rec for cont­in­u­a­tion of Ph 3 study in NASH; da­ta by YE [more in­for­ma­tion]
GenSight Biologics [SIGHT:PA] €43 MM MCap
Gene ther­a­py: reti­nal & CNS de­gen­er­a­tive patholo­gies and mi­to­chon­drial dis­ease. Fil­ing for MAA exp Q4 2019 in EU and 2020 in US. Op­to­ge­net­ic pro­gram and tar­get­ed dis­ease im­me­di­ate­ly trans­fer­able to dry AMD. Plat­form com­bines mono-ge­net­ic ther­a­py-based ap­proach w core tech­nol­o­gy plat­form and pro­pri­e­tary Mi­to­chon­drial Tar­get­ing Se­quence. [more in­for­ma­tion]
I-O; nov­el tgts in Mul­ti­ple Myelo­ma (col­lab w Take­da). Kap­paMab (MM) Ph 2b, da­ta 1H20. Kap­paMab Car-T en­ter­ing clin­ic 2019. Kap­paMab & Lamb­daMab tar­get cell sur­face pro­teins KMA and LMA on ab­nor­mal plas­ma cells. Kap­paMab: com­plete & par­tial re­spons­es in Ph 1 & 2a. Kap­pa-mab Car-T en­ter­ing clin­ic 2019. [more in­for­ma­tion]
Hutchison China MediTech Ltd ("Chi-Med") [HCM] US$3,596 MM MCap
Fruquin­tinib (VEG­FR in­hibi­tor, LLY-part­nered) for col­orec­tal can­cer was ap­proved in Chi­na in Septem­ber 2018 and Phase 3 to­p­line re­sults in NS­CLC is ex­pect­ed in late 2018. AZN has the de­ci­sion on strat­e­gy for Phase 3 reg­is­tra­tion and po­ten­tial Break­through Ther­a­py in NS­CLC in com­bi­na­tion with Ta­gris­so. [more in­for­ma­tion]
Idera Pharmaceuticals, Inc. [IDRA] US$78 MM MCap
Lead can­di­date Til­so­toli­mod (TLR 9 ag­on­ist) used in comb w Ipi in PD1 re­frac­to­ry me­lano­ma pts. En­rolling ad­dl pts in Ph 2 ex­pan­sion and Phase 3 en­roll­ment ex­pect­ed to com­plete Q4 2019. Com­bo of ipi and Til­so­toli­mod ap­pears to ac­ti­vate im­mune re­sponse in pts who have ex­haust­ed all op­tions, e.g. PD1/CPIs. Fast Track des for Til­so­toli­mod (Nov’17). [more in­for­ma­tion]
Inspirion Delivery Sciences LLC
Mor­phaBond ER™ US com­mer­cial launch Nov 2017 (FDA-ap­proved, first sin­gle-en­ti­ty abuse de­ter­rent ER mor­phine prod­uct) and Rox­y­Bond™ (FDA ap­proved, first and on­ly IR abuse-de­ter­rent opi­oid prod­uct) both li­censed to Daiichi Sankyo, Inc. Nov­el ex­tend­ed and im­me­di­ate re­lease tech­nolo­gies en­able pain med­i­ca­tions with abuse de­ter­rent fea­tures, ad­dress­ing the Opi­oid epi­dem­ic. [more in­for­ma­tion]
Iovance Biotherapeutics [IOVA] US$2,054 MM MCap
AS­CO: new in­ter­im da­ta from TIL ther­a­py LN-145 in ad­vanced cer­vi­cal can­cer (ORR 44%, 1 CR, 9 PRs, 2 uPRs) & TIL ther­a­py in ad­vanced me­lano­ma (ORR 38%, 2 CRs, 18 PRs, 1 uPR). [more in­for­ma­tion]
Kadmon Holdings, Inc. [KDMN] US$282 MM MCap
Plat­form of ROCK in­hibi­tors. ROCK2 in­hibi­tor in reg­is­tra­tion trial cGVHD; en­roll­ment com­ple­tion exp 2H19; ini­tial anal­y­sis exp YE. Ph 2 ini­ti­a­tion in scle­ro­der­ma exp in 2019. [more in­for­ma­tion]
Kine­ta is a biotech­nol­o­gy com­pany fo­cused on de­vel­op­ing nov­el drug can­di­dates in three large high need ther­a­peu­tic ar­eas: au­toim­mune dis­ease, vi­ral dis­ease and chron­ic pain. The Com­pany has five unique drug pro­grams in de­vel­op­ment and each pro­gram rep­re­sents a nov­el mech­anism-of-ac­tion and has po­ten­tial to re­sult in a new class of drug. [more in­for­ma­tion]
Marker Therapeutics [MRKR] US$264 MM MCap
A clin­i­cal-stage im­muno-on­col­o­gy com­pany with the po­ten­tial to sig­ni­f­i­cant­ly dis­rupt the cur­rent cell ther­a­py land­s­cape. Mark­er's cur­rent Mul­ti­TAA cell ther­a­py is look­ing to ini­ti­ate a Phase II study in AML in 2019. Ad­di­tio­n­al­ly, TPIV200, a T-cell vaccine is cur­rent­ly in Phase 2 for ovarian can­cer and tri­ple-neg­a­tive breast can­cer. [more in­for­ma­tion]
Medigene AG [MDG1:DB] €202 MM MCap
blue­bird bio col­lab; BLUE ini­ti­at­ing trial w/MDG MAGEA-4 can­di­date in 2020. TCRs tar­get­ing HA-1 & MAGE-A1 in de­vt. . DC vax in on­go­ing Ph 1/2; fi­nal read­out in 2019. [more in­for­ma­tion]
Medivir AB [MVIR.B-SE]
Late stage broad pipe­line: remeti­no­s­tat, Ph 3 ready top­i­cal HDAC in­hibi­tor for ear­ly-stage cu­ta­neous T-cell lym­pho­ma; MIV-711, cathepsin K in­hibi­tor for OA, Ph 2 da­ta showed dis­ease mod­i­fy­ing ef­fect on knee struc­ture; birini­pant, bi­va­lent SMAC mimet­ic read out pos­i­tive Ph 1/2 com­bo (keytru­da) da­ta Oct 18: con­firmed PR, good safe­ty. [more in­for­ma­tion]
Minerva Neurosciences, Inc. [NERV] US$211 MM MCap
Ph 3 tar­get­ing neg symp­toms as­soc w/ schi­zophre­nia; to­p­line re­sults exp 4Q19. 3 Ph 2b trials on­go­ing w/Janssen MDD/in­som­nia. (+) to­p­line Ph 2 b da­ta w/20mg dose; in­som­nia read­out exp 2Q19 [more in­for­ma­tion]
De­vel­op­ing first Glx tar­get­ed an­tide­pres­sant to ad­dress sui­ci­dal­i­ty in bipo­lar de­pres­sion. Lead can­di­date, NRX-101 in Ph 2b/3 de­vt (Break­thru Desig­na­tion, SPA and Fast Track Desig­na­tion by FDA) for Se­vere Bipo­lar De­pres­sion in pts w Acute Sui­ci­dal Idea­tion and Be­havior. Plans to pre­sent Ph 2 POC da­ta lat­er this year. [more in­for­ma­tion]
NexImmune, Inc.
Anti­gen-spe­cif­ic T cell ther­a­py. Syn­thet­ic nano­par­ti­cles de­c­o­rat­ed w a com­bo of mul­ti­ple tu­mor rel­e­vant anti­gens and co-sti­m­u­la­to­ry sig­nals en­gag­ing di­rect­ly w tar­get­ed T cells. Mul­ti­ple IND fil­ings exp H1'19. [more in­for­ma­tion]
Oncimmune [ONC:LN] £59 MM MCap
Two mar­ket­ed prod­ucts, Ear­ly­CDT®-Lung launched in 2012 and Ear­ly­CDT®-Liv­er launched in 2018, and a broad ad­vanced pipe­line of ear­ly can­cer de­tec­tion tests, in­cl. pros­tate, breast and ovarian. 156,000 Ear­ly­CDT®-Lung tests sold since launch) and Chi­na. broad and com­pre­hen­sive pa­tent port­fo­lio. [more in­for­ma­tion]
Oncopeptides AB [ONCO:ST] SKr7,492 MM MCap
Melflufen (Yga­lo): alky­lat­ing pep­tide se­lec­tive­ly tar­gets MM; su­pe­ri­or ef­fi­ca­cy vs. SOC. In­ter­im da­ta at EHA (2018) from on­go­ing Ph2 study in late stage r/r MM showed ORR of ~32%. [more in­for­ma­tion]
Oryzon Genomics [ORY:MA]
Tar­get­ing ly­sine spe­cif­ic demethy­lase 1 (LS­D1, aka KD­M1A). Lead CNS com­pound in 3 Phase 2a trials in MS, AD and bas­ket trial. Onc com­pound in 2 com­bo Phase 2a trials in AML and SCLC. Da­ta exp mid-2019 [more in­for­ma­tion]
Ph 3 study in pro­ce­du­ral se­da­tion in US. Safe­ty da­ta in ASA III/IV pa­tients in Ph 3 colonos­copy study and Ph 3 bron­chos­copy study. US fil­ing exp by part­n­er Cos­mo Phar­ma­ceu­ti­cals in 4Q18/1Q19. Ini­ti­at­ed Ph 3 in gen­er­al anes­th­e­sia in EU in Ju­ly 2018, exp com­ple­tion 2019. Fa­vor­able safe­ty pro­file of mi­da­zo­lam and at­trac­tive half-life of propo­fol: best of both in­dus­try stan­dards. [more in­for­ma­tion]
PharmaMar SA [PHM:ES]
2018 to­tal rev­enues of &eu­ro;162M. Yon­delis (soft tis­sue sar­co­ma and ovarian can­cer) com­mer­cial­ized w di­rect sales-force in EU and part­n­er­ship in US w Janssen. Zep­syre in Ph 3 trials for SCLC - da­ta due 2H19. MOA: Op­ti­mized ana­log of Yon­delis. [more in­for­ma­tion]
Pharming Group NV [PHARM:AS] €492 MM MCap
On­ly prod­uct with fu­ture po­ten­tial to be ap­proved for both pro­phy­laxis and treat­ment of at­tacks of HAE. An­nounced pos­i­tive re­sults from a ph2 study of RU­CON­EST in Con­tract-in­duced Nephro­pa­thy for pa­tients re­ceiv­ing elec­tive coro­nary an­giog­ra­phy with or with­out a per­cu­ta­neous coro­nary in­ter­ven­tion (PCI). [more in­for­ma­tion]
Phar­varis is a pre­clin­i­cal stage com­pany fo­cused on bring­ing an oral bradykinin B2 re­cep­tor an­ta­g­on­ist to pa­tients for use as an al­ter­na­tive to in­ject­ed ther­a­pies for hered­i­tary an­gioede­ma (HAE) and other B2 re­cep­tor-me­di­at­ed in­di­ca­tions. [more in­for­ma­tion]
Pieris Pharmaceuticals, Inc. [PIRS] US$184 MM MCap
An­ti­calins (en­gi­neered lipo­calin pro­teins) for re­sp & on­co dis­eas­es. Im­mi­nent da­ta for AZN-part­nered PRS-060 in­haled IL4 for mod-to-se­vere asth­ma. Cash of $128MM in the bank as of March 2019. [more in­for­ma­tion]
Plethora Solutions Holdings plc [PLE.L]
The rights to Fortacin™ for Eu­rope, Turkey, Rus­sia and cer­tain coun­tries of North Afri­ca were out-li­censed to Re­cor­dati and com­mer­cial sales start­ed in mid­dle of 2018 in Ita­ly, Ger­many, France, Por­tu­gal and Spain. [more in­for­ma­tion]
Pliant Therapeutics, Inc.
Lead pro­gram is a small molecule du­al se­lec­tive in­hibi­tor of avb6/avb1 in­te­grins for IPF, pri­mary scle­ros­ing cholan­gi­tis (PSC), and re­nal fi­bro­sis - re­ceived or­phan drug desig­na­tion and will en­ter Ph1 in De­cem­ber 2018. Se­cond pro­gram is a se­lec­tive avb1 in­hibi­tor for the treat­ment of end stage liv­er fi­bro­sis and has en­tered in­to de­vel­op­ment can­di­date se­lec­tion. [more in­for­ma­tion]
Portage Biotech [PTGEF] US$102 MM MCap
Por­tage choos­es prod­ucts with estab­lished sci­en­tif­ic ra­tio­nales and ei­ther cre­ates ma­n­age­ment teams to de­vel­op th­ese as­sets or aug­ments a com­pany’s ex­ist­ing ma­n­age­ment teams. Por­tage cre­ates much of its val­ue by de­vel­op­ing pre-proof of con­cept as­sets through proof of con­cept (POC). [more in­for­ma­tion]
Protagonist Therapeutics [PTGX] US$256 MM MCap
PTG-300, in­jectable hep­cidin mimet­ic in Ph 2 Be­ta-Tha­lassemia study with ini­tial re­sults ex­pect­ed 2H19. PTG-200, part­nered w Janssen, oral GI-re­strict­ed IL-23R an­ta­g­on­ist for Crohn’s dis­ease com­plet­ed Ph 1 in Novem­ber 2018. PN-943, oral GI-re­strict­ed al­pha4­be­ta7 in­te­grin-spe­cif­ic an­ta­g­on­ist in UC in Ph 1, with to­p­line re­sults ex­pect­ed 1H19. [more in­for­ma­tion]
Protalix BioTherapeutics [PLX] US$59 MM MCap
Lead as­set in mul­ti Ph 3 trials for Fab­ry dis­ease, part­nered glob­al­ly w Chie­si - In­ter­im Ph 3 (PRX-102) da­ta: im­prove­ment in kid­ney func­tion in pts switched from Re­pla­gal®. Ad­dl Ph 2 (in Cys­tic Fi­bro­sis) [more in­for­ma­tion]
PsiOxus Therapeutics
The ther­a­py (NG-348), us­es virus to tran­s­port two ther­a­peu­tic genes di­rect­ly in­to tu­mors to re­cruit im­mune cells in­to at­tack­ing tar­get­ed can­cer cells. Up­com­ing Mile­s­tones: - 2 pro­grams in clin­ic with read­outs in 2019 (ovarian can­cer in comb w Pa­cl­i­tax­el, car­ci­no­mas in comb w nivolumab) - 2 INDs in 2018 (NG-348 and NG-350A) - 2 INDs in 2019 (NG-641 and NG-347) [more in­for­ma­tion]
Pulse Biosciences, Inc. [PLSE] US$257 MM MCap
Med de­vice: Nano-Pulse Elec­tro-Sig­nal­ing [more in­for­ma­tion]
R2 Dermatology
Di­rec­tor of the Well­man Cen­ter of Pho­tomedicine at Mas­sachusetts Gen­er­al Hos­pi­tal in Bos­ton, a teach­ing af­fili­ate of Har­vard Med­i­cal School; of the Cu­ta­neous Bi­ol­o­gy Re­search Cen­ter in the De­part­ment of Der­ma­tol­o­gy at Mas­sachusetts Gen­er­al Hos­pi­tal; [more in­for­ma­tion]
Savara Inc. [SVRA] US$421 MM MCap
Or­phan lung dis­ease; Mol­gradex, Ph 3, in­haled GM-CSF: au­toim­mune pul­mo­nary alve­o­lar pro­tei­no­sis (aPAP), Ph 2a: non­tu­ber­cu­lous my­cobac­te­ria (NTM) lung in­fec­tion [more in­for­ma­tion]
Selvita S.A
PIM/FLT3 ki­nase in­hibi­tor in Ph 1/2 in AML (part­nered w Me­nari­ni) and sm molecule se­lec­tive CD­K8 in­hibi­tor for leukemias, lym­pho­mas, and solid tu­mors: Ph 1/2 ini­ti­a­tion exp H1 2019 [more in­for­ma­tion]
Sernova [SEOVF] US$31 MM MCap
Ser­no­va Corp. is a clin­i­cal-stage re­gen­er­a­tive medicine com­pany com­mer­cial­iz­ing prod­ucts which ben­e­fit pa­tients with chron­ic metabolic, neu­ro­log­i­cal and he­ma­to­log­i­cal dis­eas­es with first ther­a­peu­tic ap­pli­ca­tions in di­a­betes and he­mophilia. The com­pany is cur­rent­ly con­duct­ing a PI/II trial in di­a­bet­ic pa­tients with Hy­po­g­lycemia un­aware­ness. [more in­for­ma­tion]
Sol-Gel Technologies Ltd. [SLGL] US$156 MM MCap
Com­mer­cial­iz­ing brand­ed gener­ic top­i­cal drug prod­ucts (skin dis­eas­es). 2 P3 read­outs in 2019: Rosacea: mid-2019; Acne: YE [more in­for­ma­tion]
Stemline Therapeutics, Inc. [STML] US$661 MM MCap
EL­ZON­RIS, tar­get­ed ther­a­py di­rect­ed to IL-3 re­cep­tor (CD123, ap­proved for BPDC; SL-801 an oral small molecule re­v­ersi­ble in­hibi­tor of XPO1 in Ph 1 trial; and SL-701 an im­munother­a­peu­tic that com­plet­ed Ph 2 trial in pts w/2nd line GBM [more in­for­ma­tion]
STRATEC Biomedical AG [SBS:FF] €757 MM MCap
Au­to­ma­tion sys­tems and soft­ware for di­ag­nos­tics in­dus­try. In­s­talled base of >13,000 sys­tems across 20 fam­i­lies in­clud­ing PAN­THER (Ho­log­ic), Li­a­son XL (Di­a­Sorin), VI­DAS (BioMerieux) and AD­VIA (Sie­mens). Rev gen­er­at­ing and pro­f­itable; growth drivers in­cl prod­uct launch­es/ramp-ups, new tests; de­mo­graph­ics and out­sourc­ing in IVD in­dus­try. [more in­for­ma­tion]
Strongbridge Biopharma [SBBP] US$161 MM MCap
Fo­cused on rare dis­eas­es; Keveyis for PPP 2019 rev­enue gui­dance of $18-20M; Re­cor­lev 2nd Phase 3 top-line re­sults by end of 1Q 2020 with NDA sub­mis­sion planned for 3Q 2020 [more in­for­ma­tion]
Sutro Biopharma [STRO] US$242 MM MCap
Fo­cused on de­vel­op­ing next gen­er­a­tion anti­body drug con­ju­gates (ADCs) and mul­ti-spe­cif­ic anti­body-based ther­a­peu­tics for can­cer ther­a­py. STRO-001 for mul­ti­ple myelo­ma and lym­pho­mas is in Ph 1 and ex­pects ini­tial safe­ty da­ta in mid-2019. IND sub­mis­sion for STRO-002 for ovarian and en­dome­trial can­cer in Q4 2018 with the ini­ti­a­tion of a Ph 1 trial planned for ear­ly 2019. [more in­for­ma­tion]
Syneos Health [SYNH] US$4,374 MM MCap
On­ly ful­ly in­te­grat­ed bio­phar­ma­ceu­ti­cal so­lu­tions or­gani­za­tion in­cl CRO and Con­tract Com­mer­cial Or­gani­za­tion (CCO)/ (merg­er of INC Re­search & in­Ven­tiv) [more in­for­ma­tion]
Taiwan Liposome Company [TLC] US$173 MM MCap
TLC is a clin­i­cal-stage spe­cial­ty phar­ma­ceu­ti­cal com­pany ded­i­cat­ed to the de­vel­op­ment and com­mer­cial­iza­tion of nov­el nanomedicines that com­bine pro­pri­e­tary lipid-as­sem­bled drug de­liv­ery plat­forms with ap­proved ac­tive phar­ma­ceu­ti­cal in­gre­di­ents (APIs). All pro­grams ex­pect­ed to be in late or piv­o­tal stage by the end of 2020. [more in­for­ma­tion]
Targovax [TRVX:OS] NKr421 MM MCap
En­gi­neered on­co­lyt­ic virus armed w im­mune-sti­m­u­lat­ing trans­genes for pts w solid tu­mors. Ph 1 and Ph 1/2 trials on­go­ing with mul­ti­ple da­ta read­outs in 2019-2020. CMO de­vel­oped Yer­voy at BMS. [more in­for­ma­tion]
Tessa Therapeutics
On­go­ing Ph III – (na­sopha­ryn­geal can­cer), Ph I – (cer­vi­cal, mov­ing in­to Ph II); mul­ti­ple other as­sets en­ter­ing clin­ic. Key col­labs: Bay­lor, Park­er Inst, St. Jude Chil­dren’s [more in­for­ma­tion]
Trio Health
[more in­for­ma­tion]
Valbiotis [AVAL-FR]
Lead pro­gram VALE­DIA®, tar­get­ing the un­ad­dressed pre­di­a­betes mar­ket, is cur­rent­ly in a Ph 2a trial for the re­duc­tion of risk fac­tors for de­vel­op­ing Type 2 di­a­betes with re­sults ex­pect­ed mid 2019. [more in­for­ma­tion]
Vericel Corporation [VCEL] US$690 MM MCap
Ad­vanced cell ther­a­py; mar­ket­ing MA­CI (car­ti­lage re­pair) and Epi­cel (skin re­place­mentt) in TAMs of $2b+. Re­cent­ly ac­quired US com­mer­cial rights for Nexo­Brid. [more in­for­ma­tion]
Viela Bio
Lead pro­gram, Ine­bi­l­izumab, is a CD19 mAb which met the pri­mary end­point in the Ph 2b piv­o­tal study for the treat­ment of Neu­romyeli­tis Op­ti­ca. Pri­mary anal­y­sis de­mon­s­trat­ed a 77% re­duc­tion in the risk of de­vel­op­ing NMOSD at­tack in pa­tients treat­ed with ine­bi­l­izumab monother­a­py com­pared to place­bo. [more in­for­ma­tion]
vTv Therapeutics, Inc. [VTVT] US$95 MM MCap
Eval­u­at­ing TT­P399 as an add-on ther­a­py to in­sulin ther­a­py in a 12 week phase 1/2 trial in pa­tients with type 1 di­a­betes. An­a­lyz­ing re­cent Azeli­ra­gon phase 3 da­ta in or­der to move de­vel­op­ment of the ther­a­py for­ward. Re­sults from a sub­group anal­y­sis of the STEAD­FAST Alzheimer’s trial to be pre­sent­ed at CTAD dis­cuss­ing the ef­fect of Azeli­ra­gon in pa­tients with De­men­tia and Di­a­betes. [more in­for­ma­tion]
Yisheng Biopharma
Prod­ucts in de­vt in­clude YS-ON-001 (Ph 1), an IO prod­uct tar­get­ing solid tu­mors and new gen of bi­o­log­ics for pre­ven­tive and ther­a­peu­tic ben­e­fits, in­cl YS-HBV-001 (Ph 1) and PI­KA ra­bies vaccine (Ph 3), tar­get­ing hep B and ra­bies in­fec­tions. PC pro­grams in­cl bi­o­log­ics tar­get­ing in­fluen­za, her­pes zoster, ebo­la, et al. 2 bi­o­log­ics prod­ucts on mkt. [more in­for­ma­tion]